Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

TransMedics (TMDX) Cost of Revenue (2018 - 2025)

TransMedics (TMDX) has 8 years of Cost of Revenue data on record, last reported at $67.4 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 35.76% year-over-year to $67.4 million; the TTM value through Dec 2025 reached $242.7 million, up 35.23%, while the annual FY2025 figure was $242.7 million, 35.23% up from the prior year.
  • Cost of Revenue reached $67.4 million in Q4 2025 per TMDX's latest filing, up from $59.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $67.4 million in Q4 2025 and bottomed at $1.6 million in Q3 2021.
  • Average Cost of Revenue over 5 years is $27.3 million, with a median of $20.7 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: decreased 22.21% in 2021, then skyrocketed 373.89% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $2.7 million in 2021, then skyrocketed by 297.91% to $10.7 million in 2022, then skyrocketed by 211.56% to $33.2 million in 2023, then surged by 49.21% to $49.6 million in 2024, then soared by 35.76% to $67.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $67.4 million in Q4 2025, $59.2 million in Q3 2025, and $60.8 million in Q2 2025.